Navigation Links
Sangamo BioSciences Announces Presentation of Clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects Treated with SB-728-T
Date:9/12/2013

econd subject there was a transient suppression of VL at or below LOQ. The subject remains off ART.

A third subject completed the TI with 1-log decrease in VL from peak.
In three subjects, there was no reduction in VL during the TI, one completed the TI and in two the TI was terminated early due to their viral loads exceeding the upper limit allowed in the protocol.
A seventh subject has not completed TI and is still being evaluated.

The non-employee authors of these abstracts have no financial relationship with Sangamo.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and  hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Huntington's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases, and it has also established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic&re
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sangamo BioSciences to Acquire Ceregene
2. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
3. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
4. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
5. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
6. Sangamo BioSciences Reports First Quarter 2013 Financial Results
7. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
8. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
9. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
10. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
11. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... heart valves and hemodynamic monitoring, today announced that Robert ... Directors. "Bob is an ardent champion for innovation ... privilege to have him on Edwards, board as we pursue ... Edwards, chairman and CEO.  "Bob has provided a valuable perspective ...
(Date:7/30/2015)... , July 30, 2015 IRIDEX Corporation (NASDAQ: ... its second quarter 2015 financial results after the market ... conjunction with the release, the Company will host a ... p.m. Eastern Time on Thursday, August 6, ... and other business developments. Interested parties may ...
(Date:7/30/2015)... 2015  EP Global Communications, Inc. (Public OTC: EPGL) announced ... the Company about discussing EPGL,s electronic contact lens ... August 3, 2015.  Novartis CEO Joe Jimenez ... coming electronic contact lens market could be worth ... several years.  Novartis partnered with Google in 2014 ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2
(Date:7/31/2015)... ... 2015 , ... Recently touted by Becker’s Healthcare as one ... , Jvion continues to disrupt the predictive analytic and big data market using ... population level illness to drive prevention and better health outcomes. Most recently, Jvion ...
(Date:7/31/2015)... ... 2015 , ... Jacksonville-based drug and alcohol rehabilitation center, Lakeview ... The medical community, social workers, law enforcement, and government officials are all invited ... effort to better understand and combat sex trafficking. Lead by sex trafficking expert ...
(Date:7/31/2015)... ... ... article published July 27 on My News LA, a fire that broke out ... fire department before it caused major damage throughout the building. The article also notes that ... a fire alarm system that tipped off fire fighters so they could arrive at the ...
(Date:7/31/2015)... ... July 31, 2015 , ... As part of their company ... and support of animal welfare organizations is essential to the longevity of their business. ... in the National Association of Professional Pet Sitters (NAPPS) annual Presents 4 Pets supply ...
(Date:7/31/2015)... Athens, GA (PRWEB) , ... July 31, 2015 , ... ... help stamp out bullying across Georgia through the Girl Scout "Be a Friend First" ... program, on Thursday, July 30. , “Peach State Health Plan and our parent ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2
... , , , ... Clinically Superior When Its Own FDA-Approved Label Said Otherwise; First-Ever ... , PHILADELPHIA, Sept. 2 Pfizer Inc. ignored a ... clinically superior to the significantly less expensive, generic vancomycin when its ...
... , , , ... DIET ), a leading provider of online weight loss services, ... creative boutique that specializes in DRTV commercials, to lead creative turnaround beginning ... service. , , "We are really impressed by ...
... 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:, ... China, announced,today that it has signed an agreement with ... collaborate on marketing,efforts and possible vaccine supply efforts to ... The agreement follows meetings between ...
... of the body,s immune system in the development of diseases ... skin cancer), type 1 diabetes, autoimmune liver disease, and in ... paved the way for a pioneering research programme which aims ... find ways to extract specific cells which play a role ...
... , , , , ... STRM ) announced today that it will release second quarter ... on Wednesday, September 9, 2009 after the market closes. The Company will ... Wednesday, September 9 at 4:30 p.m. ET. , , ...
... Sept. 2 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today ... of BioMarin, will present a company update at the Thomas Weisel Partners ... ET. , , Interested parties may access ... of the BioMarin website, www.BMRN.com . A replay ...
Cached Medicine News:Health News:Sheller, P.C. Law Firm Instrumental in Pfizer's $2.3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 2Health News:Sheller, P.C. Law Firm Instrumental in Pfizer's $2.3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 3Health News:Sheller, P.C. Law Firm Instrumental in Pfizer's $2.3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 4Health News:Sheller, P.C. Law Firm Instrumental in Pfizer's $2.3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 5Health News:eDiets.com Selects Karlin+Pimsler to Lead Creative Turnaround 2Health News:Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea 2Health News:Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea 3Health News:Biomedical Research Centre developing enhanced cells as therapies 2Health News:Biomedical Research Centre developing enhanced cells as therapies 3Health News:Streamline Health to Announce Second Quarter Fiscal Year 2009 Financial Results on Wednesday, September 9, 2009 2Health News:Streamline Health to Announce Second Quarter Fiscal Year 2009 Financial Results on Wednesday, September 9, 2009 3Health News:BioMarin to Present at the Thomas Weisel Partners Healthcare Conference 2
... System RS 800 can sort different specimen ... sorting are not necessary anymore and all ... a very timesaving and economical way ... a Tube Type Identification via Cap Recognition ...
... detect sequences of the following viruses: ... and 3; influenza virus A and ... and B. Laboratories may use ... *Analyte Specific Reagents. Analytical ...
... Alert Detection Reagents provide molecular labs a ... assays. By using our MGB technology, combined ... is now able to provide molecular labs ... sequences of specific organisms or genetic mutations ...
... for the detection of two genetic ... mutation on the Factor V (Leiden) ... the Prothrombin gene. Laboratories may use ... *Analyte Specific Reagents. Analytical ...
Medicine Products: